ImmunoGen, Inc. engages in the research and development of targeted therapeutics for the treatment of cancer using cancer biology, monoclonal antibodies, and highly potent cell-killing agents. The company develops its products using its Targeted Antibody Payload (TAP) technology. Its product candidates include Trastuzumab emtansine (T-DM1), a Phase III clinical trial product for HER2+ breast cancer; lorvotuzumab mertansine (IMGN901), a Phase I clinical trial product, which targets CD56 found on small-cell lung cancer, Merkel cell carcinoma, multiple myeloma, ovarian cancers, carcinoid tumors, and other cancers of neuroendocrine origin; IMGN529, a pre-investigational new drug stage drug for CD37+ B-cell malignancies, such as non-Hodgkin's lymphoma; and IMGN853, a preclinical stage product for cancers that overexpress folate receptor 1, including ovarian cancer. The company’s earlier-stage compounds in development stage comprise SAR3419, a Phase I clinical trial product for CD19+ B-cell malignancies, including non-Hodgkin's lymphoma; SAR650984, a Phase I clinical trial product for CD38+ hematological malignancies; SAR566658, a phase one clinical trial product for DS6+ solid tumors; and BT-062, a Phase I product for multiple myeloma. It has collaboration agreements with Amgen, Inc.; Bayer Schering Pharma AG; Biogen Idec MA Inc.; Biotest AG; Genentech, Inc.; Novartis Institutes for BioMedical Research, Inc.; and sanofi-aventis U.S. LLC. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Key Statistics